These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


650 related items for PubMed ID: 12631596

  • 1. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
    Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, Gleason MJ, Kim HW.
    Clin Cancer Res; 2003 Mar; 9(3):981-90. PubMed ID: 12631596
    [Abstract] [Full Text] [Related]

  • 2. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
    Levin VA, Uhm JH, Jaeckle KA, Choucair A, Flynn PJ, Yung WKA, Prados MD, Bruner JM, Chang SM, Kyritsis AP, Gleason MJ, Hess KR.
    Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
    [Abstract] [Full Text] [Related]

  • 3. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
    Prados MD, Seiferheld W, Sandler HM, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ.
    Int J Radiat Oncol Biol Phys; 2004 Mar 15; 58(4):1147-52. PubMed ID: 15001257
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study.
    Brandes AA, Tosoni A, Vastola F, Pasetto LM, Coria B, Danieli D, Iuzzolino P, Gardiman M, Talacchi A, Ermani M.
    Cancer; 2004 Nov 01; 101(9):2079-85. PubMed ID: 15372474
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
    Soffietti R, Nobile M, Rudà R, Borgognone M, Costanza A, Laguzzi E, Mutani R.
    Cancer; 2004 Feb 15; 100(4):807-13. PubMed ID: 14770438
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.
    Levin VA, Prados MR, Wara WM, Davis RL, Gutin PH, Phillips TL, Lamborn K, Wilson CB.
    Int J Radiat Oncol Biol Phys; 1995 Apr 30; 32(1):75-83. PubMed ID: 7721642
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].
    Afra D, Sipos L, Vitanovics D.
    Ideggyogy Sz; 2002 Jan 20; 55(1-2):38-44. PubMed ID: 12122942
    [Abstract] [Full Text] [Related]

  • 13. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
    Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ.
    Cancer; 2005 Feb 15; 103(4):802-9. PubMed ID: 15637687
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.
    Levin VA, Yung WK, Bruner J, Kyritsis A, Leeds N, Gleason MJ, Hess KR, Meyers CA, Ictech SA, Chang E, Maor MH.
    Int J Radiat Oncol Biol Phys; 2002 May 01; 53(1):58-66. PubMed ID: 12007942
    [Abstract] [Full Text] [Related]

  • 15. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH).
    Gnekow AK, Kortmann RD, Pietsch T, Emser A.
    Klin Padiatr; 2004 May 01; 216(6):331-42. PubMed ID: 15565548
    [Abstract] [Full Text] [Related]

  • 16. [Chemo-radiotherapy for malignant brain tumors].
    Kochi M, Ushio Y.
    Gan To Kagaku Ryoho; 2002 May 01; 29(5):669-76. PubMed ID: 12040669
    [Abstract] [Full Text] [Related]

  • 17. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.
    Weller M, Müller B, Koch R, Bamberg M, Krauseneck P, Neuro-Oncology Working Group of the German Cancer Society.
    J Clin Oncol; 2003 Sep 01; 21(17):3276-84. PubMed ID: 12947063
    [Abstract] [Full Text] [Related]

  • 18. [A clinical evaluation of combination therapy with radiation, MCNU, carboplatin and IFN-beta or with radiation, MCNU, carboplatin, etoposide and IFN-beta for malignant gliomas].
    Mizumatsu S, Matsumoto K, Maeda Y, Tamiya T, Furuta T, Ohmoto T.
    Gan To Kagaku Ryoho; 1998 Nov 01; 25(13):2055-60. PubMed ID: 9838907
    [Abstract] [Full Text] [Related]

  • 19. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
    Gorlia T, Delattre JY, Brandes AA, Kros JM, Taphoorn MJ, Kouwenhoven MC, Bernsen HJ, Frénay M, Tijssen CC, Lacombe D, van den Bent MJ.
    Eur J Cancer; 2013 Nov 01; 49(16):3477-85. PubMed ID: 23896377
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 33.